
Schematic diagram of DHAAD alleviating EAE by inhibiting the Th1/Th17-mediated pro-inflammatory axis. DHAAD attenuates Th1/Th17-driven inflammatory responses in the periphery and central nervous system. It reduces CD4+ T cell subsets and pro-inflammatory cytokines in the spleen and lymph nodes. This limits immune cell infiltration into the CNS and alleviates EAE-associated demyelination.
ABSTRACT
Multiple sclerosis (MS) is a central nervous system (CNS)-specific chronic disorder, characterized by T cell-mediated demyelination and neuroinflammation. Dihydroartemisinin, a semisynthetic artemisinin derivative, has been reported as a potential MS treatment for its immunomodulatory activity. This work investigated dihydroartemisinin acetal dimer (DHAAD), a novel dihydroartemisinin derivative, for MS therapy and explored possible mechanistic insights. A library of 14 small-molecule compounds was screened through in vitro Th1/Th17 differentiation assays. Experimental autoimmune encephalomyelitis (EAE), an animal model for MS, was induced in mice with the MOG35
−
55 peptide. The compound identified through screening was orally administered to mice at various doses. Its therapeutic effects at the tissue and cellular levels were assessed using histopathological analysis and flow cytometry, respectively, while the effects on cytokine levels and signature gene expression were evaluated through enzyme-linked immunosorbent assay and quantitative polymerase chain reaction, respectively. DHAAD was identified as effectively inhibiting Th1/Th17 cell differentiation. DHAAD treatment mitigated EAE manifestations in mice (reduced clinical scores, leukocyte infiltration, and CNS demyelination) and suppressed Th1/Th17 cell populations in both CNS and peripheral compartments, concurrently reducing IFN-γ and IL-17A secretion. Upon MOG35
−
55 re-stimulation, splenocytes and lymph node cells from treated mice also exhibited decreased IFN-γ and IL-17A production. Furthermore, DHAAD administration downregulated the genes driving Th1/Th17 cell differentiation and those executing their pro-inflammatory functions. DHAAD alleviates EAE symptoms by suppressing pro-inflammatory Th1/Th17 differentiation pathways through its immunosuppressive effects in the CNS and peripheral sites, thereby ameliorating inflammation and revealing its application potential in MS.